Production (Stage)
Adaptimmune Therapeutics plc
ADAP
$0.2801
$0.00572.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.89% | -54.88% | 61.37% | 425.03% | -4,781.76% |
| Total Depreciation and Amortization | -12.86% | -1.25% | -2.56% | 22.85% | 53.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -103.71% | 455.71% | 161.78% | 113.30% | 35.41% |
| Change in Net Operating Assets | -306.11% | -9.66% | -869.73% | -364.79% | 124.29% |
| Cash from Operations | -108.43% | -133.06% | -20.58% | 208.31% | 14.30% |
| Capital Expenditure | -1,079.41% | 73.52% | 50.52% | 65.30% | 95.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 16,645.70% | -87.85% | -214.38% | 99.22% | -100.51% |
| Cash from Investing | 11,595.53% | -88.02% | -215.20% | -127.58% | -100.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.55% | -98.65% | -99.83% | -14.29% | 14,815.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -186.61% | -98.65% | 4,094.80% | 174,985.71% | 14,815.82% |
| Foreign Exchange rate Adjustments | 233.65% | -151.43% | 65.89% | 89.47% | -170.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,338.87% | -148.60% | -840.01% | 272.51% | -129.46% |